Biotechnology
Price
$220.83
-1.64%Market Cap
$32.66B
Day High
$223.82
Day Low
$219.82
Biogen reported 2026-Q2 total revenue of $2,736.0 million (+3.4% YoY), driven by the addition of Apellis products and growth in rare disease therapies, though net profitability fell sharply due to acquisition step-up costs and higher operating and IPR&D expenses.
Key risk: Generic and Biosimilar Competition
Competition from generic entrants for TECFIDERA following patent revocation in Europe and biosimilar versions of TYSABRI significantly reduced product revenues and could continue to cause price and volume declines.
Other Biotechnology companies